1. Home
  2. PXLW vs KPTI Comparison

PXLW vs KPTI Comparison

Compare PXLW & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PXLW
  • KPTI
  • Stock Information
  • Founded
  • PXLW 1997
  • KPTI 2008
  • Country
  • PXLW United States
  • KPTI United States
  • Employees
  • PXLW N/A
  • KPTI N/A
  • Industry
  • PXLW Semiconductors
  • KPTI Biotechnology: Pharmaceutical Preparations
  • Sector
  • PXLW Technology
  • KPTI Health Care
  • Exchange
  • PXLW Nasdaq
  • KPTI Nasdaq
  • Market Cap
  • PXLW 50.2M
  • KPTI 44.5M
  • IPO Year
  • PXLW 2000
  • KPTI 2013
  • Fundamental
  • Price
  • PXLW $10.28
  • KPTI $6.18
  • Analyst Decision
  • PXLW Strong Buy
  • KPTI Buy
  • Analyst Count
  • PXLW 3
  • KPTI 6
  • Target Price
  • PXLW $13.67
  • KPTI $39.80
  • AVG Volume (30 Days)
  • PXLW 162.2K
  • KPTI 185.7K
  • Earning Date
  • PXLW 11-11-2025
  • KPTI 11-04-2025
  • Dividend Yield
  • PXLW N/A
  • KPTI N/A
  • EPS Growth
  • PXLW N/A
  • KPTI N/A
  • EPS
  • PXLW N/A
  • KPTI N/A
  • Revenue
  • PXLW $33,961,000.00
  • KPTI $137,269,000.00
  • Revenue This Year
  • PXLW N/A
  • KPTI $3.67
  • Revenue Next Year
  • PXLW $25.33
  • KPTI $9.40
  • P/E Ratio
  • PXLW N/A
  • KPTI N/A
  • Revenue Growth
  • PXLW N/A
  • KPTI N/A
  • 52 Week Low
  • PXLW $4.67
  • KPTI $3.51
  • 52 Week High
  • PXLW $15.03
  • KPTI $16.95
  • Technical
  • Relative Strength Index (RSI)
  • PXLW 53.16
  • KPTI 51.26
  • Support Level
  • PXLW $7.97
  • KPTI $5.70
  • Resistance Level
  • PXLW $13.50
  • KPTI $6.85
  • Average True Range (ATR)
  • PXLW 1.32
  • KPTI 0.61
  • MACD
  • PXLW 0.31
  • KPTI -0.15
  • Stochastic Oscillator
  • PXLW 43.90
  • KPTI 19.59

About PXLW Pixelworks Inc.

Pixelworks Inc is a provider of visual processing semiconductor and software solutions that enable consistently high-quality and authentic viewing experiences in a wide variety of applications. The company defines its key target markets as Mobile (smartphone and tablet), Home and Enterprise (projectors, personal video recorders (PVR), and over-the-air (OTA) streaming devices), and Cinema (creation, remastering, and delivery of digital video content). The company operates in one segment: the design, development, marketing and sale of IC solutions for use in electronic display devices. The company generates its revenue from two broad product markets: the Mobile market and the Home and Enterprise market. The majority of the revenue is earned in Japan.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: